The United States market has experienced a robust performance, rising 4.0% over the last week and 39% over the past year, with earnings anticipated to grow by 16% annually. In this thriving environment, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name	Current Price	Fair Value (Est)	Discount (Est)
WesBanco (WSBC)	$36.36	$71.92	49.4%
Vertex (VERX)	$12.35	$24.16	48.9%
Robert Half (RHI)	$27.44	$54.26	49.4%
Live Oak Bancshares (LOB)	$37.46	$74.18	49.5%
Golar LNG (GLNG)	$51.84	$102.93	49.6%
DNOW (DNOW)	$11.95	$23.54	49.2%
Commvault Systems (CVLT)	$94.23	$184.67	49%
Bitgo Holdings (BTGO)	$11.18	$22.04	49.3%
BioHarvest Sciences (BHST)	$4.35	$8.62	49.5%
Betterware de MéxicoP.I. de (BWMX)	$18.78	$37.08	49.4%

Let's explore several standout options from the results in the screener.

Fifth Third Bancorp (FITB)

Overview: Fifth Third Bancorp is the bank holding company for Fifth Third Bank, National Association, offering a variety of financial products and services in the United States, with a market cap of $45.60 billion.

Operations: The company generates revenue through several segments, including Commercial Banking ($3.61 billion), Wealth and Asset Management ($704 million), and Consumer and Small Business Banking ($5.15 billion).

Estimated Discount To Fair Value: 48.2%

Fifth Third Bancorp appears undervalued based on discounted cash flow analysis, trading at US$50.34, significantly below its estimated future cash flow value of US$97.22. Despite a decline in net income to US$165 million for Q1 2026 from US$515 million a year ago, the bank's earnings are projected to grow at 21.8% annually, outpacing the broader U.S. market growth forecast of 16%.

Insulet (PODD)

Overview: Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes both in the United States and internationally, with a market cap of $14.11 billion.

Operations: The company's revenue primarily comes from its drug delivery systems segment, which generated $2.71 billion.

Estimated Discount To Fair Value: 29.9%

Insulet is trading at US$203.73, below its estimated future cash flow value of US$290.8, suggesting undervaluation based on cash flows. Despite a recent dip in profit margins and net income, earnings are forecast to grow 23.1% annually, surpassing the U.S. market's growth rate of 16%. Recent executive changes and product innovations may bolster commercial strategy and operational performance, though challenges like the Omnipod 5 Pod recall highlight ongoing quality control efforts.

Glaukos (GKOS)

Overview: Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for glaucoma, corneal disorders, and retinal diseases globally, with a market cap of approximately $7.24 billion.

Operations: The company's revenue is primarily derived from the development and commercialization of ophthalmic therapies, amounting to $507.44 million.

Estimated Discount To Fair Value: 48.8%

Glaukos, trading at US$124.79, is significantly undervalued compared to its estimated future cash flow value of US$243.51. Revenue is projected to grow at 19% annually, outpacing the broader U.S. market's growth rate of 10.9%. Recent product launches like Epioxa for keratoconus and regulatory advancements with iDose TR highlight potential revenue drivers despite current net losses and a low forecasted return on equity of 6.7% in three years.

Make It Happen

• Take a closer look at our Undervalued US Stocks Based On Cash Flows list of 157 companies by clicking here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.